Tiaa Fsb bought a new position in ABIOMED, Inc. (NASDAQ:ABMD) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 12,259 shares of the medical equipment provider’s stock, valued at approximately $1,757,000.

Several other institutional investors have also bought and sold shares of the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in shares of ABIOMED by 0.5% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 5,947 shares of the medical equipment provider’s stock worth $852,000 after purchasing an additional 32 shares in the last quarter. BB&T Securities LLC increased its holdings in shares of ABIOMED by 1.0% in the 2nd quarter. BB&T Securities LLC now owns 4,154 shares of the medical equipment provider’s stock worth $595,000 after purchasing an additional 43 shares in the last quarter. Teacher Retirement System of Texas increased its holdings in shares of ABIOMED by 1.6% in the 2nd quarter. Teacher Retirement System of Texas now owns 3,294 shares of the medical equipment provider’s stock worth $472,000 after purchasing an additional 51 shares in the last quarter. Capstone Asset Management Co. increased its holdings in shares of ABIOMED by 1.1% in the 2nd quarter. Capstone Asset Management Co. now owns 6,410 shares of the medical equipment provider’s stock worth $919,000 after purchasing an additional 70 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its holdings in shares of ABIOMED by 1.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 7,842 shares of the medical equipment provider’s stock worth $982,000 after purchasing an additional 95 shares in the last quarter. 89.69% of the stock is owned by institutional investors and hedge funds.

In related news, Director Paul Thomas sold 10,000 shares of the company’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $154.71, for a total value of $1,547,100.00. Following the transaction, the director now directly owns 12,172 shares of the company’s stock, valued at approximately $1,883,130.12. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO David M. Weber sold 16,500 shares of the company’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $147.63, for a total value of $2,435,895.00. Following the completion of the transaction, the chief operating officer now directly owns 125,122 shares in the company, valued at $18,471,760.86. The disclosure for this sale can be found here. Over the last three months, insiders sold 50,500 shares of company stock worth $7,603,342. 7.00% of the stock is owned by insiders.

ABIOMED, Inc. (NASDAQ ABMD) opened at 163.96 on Friday. The stock has a 50 day moving average price of $152.81 and a 200-day moving average price of $138.79. ABIOMED, Inc. has a 1-year low of $95.14 and a 1-year high of $164.60. The stock has a market capitalization of $7.23 billion, a P/E ratio of 95.88 and a beta of 0.22.

ABIOMED (NASDAQ:ABMD) last released its earnings results on Thursday, July 27th. The medical equipment provider reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $0.03. ABIOMED had a return on equity of 13.03% and a net margin of 16.13%. The firm had revenue of $132.47 million for the quarter, compared to the consensus estimate of $130.83 million. During the same period in the prior year, the firm earned $0.29 EPS. The firm’s revenue was up 28.6% on a year-over-year basis. Equities research analysts expect that ABIOMED, Inc. will post $2.24 EPS for the current year.

ABMD has been the subject of a number of research analyst reports. Piper Jaffray Companies set a $145.00 target price on ABIOMED in a report on Tuesday, July 4th. BidaskClub raised ABIOMED from a “hold” rating to a “buy” rating in a report on Thursday, August 10th. Jefferies Group LLC reissued a “buy” rating and issued a $175.00 target price on shares of ABIOMED in a report on Tuesday, August 29th. Morgan Stanley reissued an “equal weight” rating and issued a $140.00 target price (up previously from $135.00) on shares of ABIOMED in a report on Monday, July 10th. Finally, Zacks Investment Research lowered ABIOMED from a “buy” rating to a “hold” rating in a report on Monday, August 7th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. ABIOMED currently has an average rating of “Buy” and a consensus price target of $158.29.

WARNING: This story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/09/23/tiaa-fsb-buys-new-holdings-in-abiomed-inc-abmd.html.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.